Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
Globe Newswire•30/10/2026•09:05 ET
1
Key Highlights
- ➤Akari will present its RNA-splicing ADC strategy at the November 4–6 ADC Payload Summit
- ➤PH1 preclinical models showed cancer-cell killing alongside innate and adaptive immune activation
- ➤AKTX-101 is Akari’s lead TROP2-PH1 ADC candidate
- ➤Akari initiated IND-enabling studies for AKTX-101, targeting a first-in-human trial by mid-2027
- ➤AKTX-102 is a CEACAM5-targeting ADC candidate using Akari’s PH1 payload
Expert Statements
Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics
“Advancing ADC innovation requires exploring novel mechanisms that can improve outcomes for patients. Our PH1 platform is designed to combine targeted cancer-cell killing with immune activation, offering a differentiated approach to ADC development. We look forward to sharing the scientific rationale and preclinical findings behind our RNA-splicing payload strategy with researchers and industry leaders focused on the next generation of ADCs.”
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation
Satyajit Mitra, Executive Director, Head of Oncology, to discuss differentiated payload mechanisms and preclinical findings supporting next-generation ADC development
Get started
Create a free account to read the full story.